This biotechnology company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn’t been in trend either. Thursday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
Enzymotec currently has a Zacks Rank #4 (Sell) and its Earnings ESP is 0.00%.
A stock worth considering in the Med-Products space is LeMaitre Vascular, Inc. (LMAT) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment